Table 1. Subject characteristics at the time of blood sampling and genotyping chip used.
| MDC ( n = 2,060) | SAHLSIS ( n = 756) | SAHLSIS a ( n = 444) | Total (3,260) | |
|---|---|---|---|---|
| Cases, n (%) | 0 (0) | 166 (22) | 444 (100) | 600 (18.4) |
| Age, median (IQR) | 58 (53–63) | 59 (52–64) | 58 (50–63) | 58 (52–64) |
| Male gender, n (%) | 818 (39.7) | 477 (63.1) | 293 (66) | 1,588 (48.7) |
| Hypertension, n (%) | 1,304 (63) | 333 (44.2) | 245 (56.1) | 1,882 (57.9) |
| Diabetes mellitus, n (%) | 192 (9.3) | 66 (8.8) | 81 (18.2) | 339 (10.4) |
| Current smoking, n (%) | 405 (22.4) | 174 (23) | 168 (38) | 792 (24.7) |
| Hyperlipidaemia, n (%) | 1,847 (90.2) | 512 (69.3) | 304 (75.1) | 2,663 (83.4) |
| Intact TAFI, n (%) | 2,052 (99.6) | 748 (98.9) | 404 (91.0) | 3,204 (98.3) |
| Median (IQR) | 72 (61–85) | 90 (77–101) | 95 (83–114) | 79 (65–95) |
| TAFI-AP, n (%) | 2,060 (100) | 748 (98.9) | 404 (91.0) | 3,212 (98.5) |
| Median (IQR) | 96 (67–132) | 105 (93–122) | 124 (105–148) | 103 (80–131) |
| Genotyping platform | Human OmniExpress Exome v1.0 | Human OmniExpress Exome v1.0 | Human Omni 5M Exome v1.0 | Imputed to the UK10K + 1000 Genomes Ph3 |
Abbreviations: MDC, Malmö Diet and Cancer Study; SAHLSIS, Sahlgrenska Academy Study on Ischemic Stroke; TAFI-AP, thrombin-activatable fibrinolysis inhibitor activation peptide.
Note: Intact TAFI expressed as relative levels; TAFI-AP, TAFI activation peptide, expressed as relative levels.
a
Included in the NINDS Stroke Genetic Network (SiGN) study.